WESPAC Advisors LLC acquired a new position in Cencora, Inc. (NYSE:COR - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 6,508 shares of the company's stock, valued at approximately $1,810,000. Cencora makes up about 1.5% of WESPAC Advisors LLC's investment portfolio, making the stock its 9th largest holding.
Other hedge funds have also bought and sold shares of the company. Cornerstone Planning Group LLC boosted its position in Cencora by 106.7% in the 1st quarter. Cornerstone Planning Group LLC now owns 93 shares of the company's stock worth $26,000 after purchasing an additional 48 shares in the last quarter. Hoey Investments Inc. purchased a new position in shares of Cencora during the 1st quarter valued at approximately $28,000. Banque Transatlantique SA purchased a new position in shares of Cencora during the 4th quarter valued at approximately $29,000. SBI Securities Co. Ltd. purchased a new position in shares of Cencora during the 4th quarter valued at approximately $30,000. Finally, Vermillion Wealth Management Inc. purchased a new position in shares of Cencora during the 4th quarter valued at approximately $38,000. Hedge funds and other institutional investors own 97.52% of the company's stock.
Cencora Trading Down 0.8%
Shares of COR traded down $2.25 during midday trading on Friday, reaching $295.07. The company had a trading volume of 970,795 shares, compared to its average volume of 1,509,975. Cencora, Inc. has a 1-year low of $218.65 and a 1-year high of $309.35. The stock has a market cap of $57.19 billion, a PE ratio of 34.23, a price-to-earnings-growth ratio of 1.47 and a beta of 0.57. The firm has a 50 day simple moving average of $291.91 and a 200-day simple moving average of $269.69. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 6.01.
Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The business had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. During the same period last year, the company earned $3.80 EPS. The company's revenue for the quarter was up 10.3% on a year-over-year basis. Research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.
Cencora Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date of this dividend was Friday, May 16th. Cencora's dividend payout ratio (DPR) is presently 25.52%.
Wall Street Analyst Weigh In
A number of research analysts have recently issued reports on COR shares. Jefferies Financial Group increased their target price on Cencora from $275.00 to $300.00 and gave the company a "hold" rating in a research report on Monday, June 30th. UBS Group increased their target price on Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. Robert W. Baird increased their target price on Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Wells Fargo & Company upgraded Cencora from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $274.00 to $337.00 in a research report on Tuesday, June 3rd. Finally, Morgan Stanley set a $288.00 price objective on Cencora in a research note on Tuesday, April 15th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $306.33.
Read Our Latest Research Report on COR
Insiders Place Their Bets
In related news, CEO Robert P. Mauch sold 4,969 shares of the firm's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the completion of the sale, the chief executive officer directly owned 47,582 shares of the company's stock, valued at approximately $13,766,900.06. This trade represents a 9.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Steven H. Collis sold 14,579 shares of the firm's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total value of $4,266,106.98. Following the sale, the chairman directly owned 311,913 shares of the company's stock, valued at $91,271,982.06. The trade was a 4.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 34,127 shares of company stock valued at $9,812,296 over the last ninety days. Corporate insiders own 10.80% of the company's stock.
About Cencora
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Articles
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
